Document is current
Any future updates will be listed below
-
Authors
Li, Zhenrui https://orcid.org/0000-0001-7172-7643
Xu, Beisi https://orcid.org/0000-0003-0099-858X
Sharma, Piyush https://orcid.org/0000-0003-1185-9534
Guy, Cliff
Boada-Romero, Emilio https://orcid.org/0000-0003-2482-076X
Verbist, Katherine
Guo, Ao https://orcid.org/0000-0003-2597-7558
Mari, Luigi https://orcid.org/0000-0002-2903-7689
Poudel, Suresh
Yang, Mao
Green, Douglas R. https://orcid.org/0000-0002-7332-1417
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA231620)
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 3 February 2026
First Online: 3 March 2026
Competing interests
: D.R.G. declares consultation for Ventus Therapeutics, ASHA Therapeutics and Mycos and research support from AMGEN. The other authors declare no competing interests.
